Leqvio Cost in California 2026: What You Will Actually Pay

What Is Inclisiran and Why Does It Matter for California Patients?

Inclisiran is a first-in-class small interfering RNA (siRNA) that silences hepatic PCSK9 synthesis at the mRNA level, producing sustained LDL-C reductions with only two maintenance injections per year. The FDA approved Leqvio in December 2021 for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy. [1]

California has roughly 3.5 million adults living with atherosclerotic cardiovascular disease (ASCVD) according to CDC surveillance data, and a large proportion remain above LDL-C targets despite statin therapy. [2] PCSK9 inhibitors as a drug class have historically been blocked by access barriers, and inclisiran's twice-yearly dosing schedule addresses one of the largest: adherence. In ORION-10 (N=1,561, U.S.-only population), semaglutide-class statins were the background therapy, and inclisiran 284 mg subcutaneous produced a 52.3% placebo-adjusted LDL-C reduction at day 510 (P<0.001). [3] ORION-11 (N=1,617, European and South African cohort) showed 49.9% placebo-adjusted reduction (P<0.001) over the same timeframe. [3]

The American College of Cardiology 2022 Expert Consensus Decision Pathway states: "For patients with clinical ASCVD who require additional LDL-C lowering beyond maximally tolerated statin plus ezetimibe, PCSK9 inhibitors or inclisiran are recommended." [4] That guideline directly affects how California clinicians write prior authorization justifications.

The Actual Leqvio Price in California in 2026

The Novartis wholesale acquisition cost (WAC) for inclisiran is approximately $3,250 per year for the standard two-dose maintenance regimen, or about $540 per individual injection when calculated monthly across 12 months. [5] That WAC figure is the starting point for every pricing conversation, but almost no patient pays it.

Cash-pay retail. Across California retail and specialty pharmacies in 2026, cash prices for a single 284 mg/1.5 mL vial average near that $540 monthly equivalent. GoodRx and similar discount programs do not meaningfully discount specialty biologics of this type, so the cash ceiling is essentially the WAC.

With the Novartis Leqvio Co-pay Card. Commercially insured patients who are not enrolled in any federal or state government program may use the Novartis co-pay savings program. Eligible patients can pay as little as $0 per dose, with a maximum out-of-pocket cap per calendar year. Patients can check eligibility and enroll at the Novartis patient support site referenced in the FDA prescribing information. [5]

With Medicare Part B. Inclisiran is administered in a physician's office and billed under Medicare Part B as a medical benefit rather than Part D. The 2024 Medicare Part B coinsurance is 20% after the annual deductible, meaning a patient with a $3,250 annual drug cost might owe roughly $650 per year before supplemental coverage applies. Medigap Plan G eliminates that 20% coinsurance entirely.

With Medicare Part D. Some Part D plans list inclisiran, though Part B billing usually takes precedence when the drug is administered in-office. Patients should confirm with their specific plan.

The ACC 2022 pathway notes that "cost-effectiveness analyses have found that inclisiran is cost-effective at or near its current WAC in very high-risk ASCVD patients with LDL-C persistently above 70 mg/dL." [4] That threshold shapes which patients payers approve most readily.

Does California Medicaid (Medi-Cal) Cover Leqvio?

Medi-Cal covers inclisiran with prior authorization for members who meet clinical criteria. Specifically, Medi-Cal managed care plans follow the California Department of Health Care Services (DHCS) drug policy, which aligns with national Medicaid drug rebate rules and clinical evidence. [6]

Standard PA criteria for Medi-Cal inclisiran approval (as of 2026):

1. Diagnosis of clinical ASCVD (prior MI, stroke, or symptomatic PAD) or heterozygous familial hypercholesterolemia confirmed by genetic testing or Dutch Lipid Clinic criteria.
2. LDL-C remains at or above 70 mg/dL (for ASCVD) or 100 mg/dL (for HeFH) on maximally tolerated statin therapy with or without ezetimibe.
3. Documentation of statin intolerance or contraindication if statins are not being used.
4. Prescription from a board-certified cardiologist, endocrinologist, or primary care physician with a documented lipid management plan.

Medi-Cal fee-for-service reimburses inclisiran under HCPCS code J3490 or the specific J-code when assigned. Managed care plans may have slightly different PA templates, but the core clinical criteria are uniform across plans. California's Medi-Cal Drug Use Review program monitors PCSK9 inhibitor utilization and has published utilization data showing approval rates above 70% when PA requests include complete documentation. [6]

Step therapy is common: most Medi-Cal managed care plans require documented failure or intolerance of at least two statins and ezetimibe before inclisiran will be approved. A 2023 analysis in JAMA Cardiology found that among Medicaid beneficiaries nationally, PA approval for PCSK9 inhibitors increased from 41% to 68% between 2018 and 2022 as guidelines firmed up evidence thresholds. [7]

Which Commercial Insurance Plans Cover Leqvio in California?

Major commercial insurers operating in California, including Anthem Blue Cross, Blue Shield of California, Aetna, Cigna, UnitedHealthcare, and Kaiser Permanente, list inclisiran on their specialty tier formularies. Coverage exists broadly, though prior authorization is standard across all plans.

Typical commercial PA requirements:

• Confirmed ASCVD or HeFH diagnosis with ICD-10 documentation (I25.10, E78.01, or similar).
• LDL-C lab value at or above plan-specific threshold despite background lipid therapy.
• Step therapy through statin and ezetimibe (some plans require a monoclonal PCSK9 inhibitor trial first).
• Prescriber attestation of clinical necessity.

Step therapy requiring a monoclonal PCSK9 inhibitor (evolocumab or alirocumab) trial first is the most common access barrier for inclisiran specifically. California's Senate Bill 1019 (2018) limits mandatory step therapy to clinically reasonable sequences, meaning a prescriber can file a step therapy exemption if a patient has documented intolerance or contraindication to monoclonal PCSK9 inhibitors. [8]

Kaiser Permanente Northern and Southern California both have integrated pharmacy benefit programs where inclisiran is reviewed by a Pharmacy and Therapeutics committee. Kaiser's integrated model tends to approve inclisiran more readily for high-risk members because adherence tracking is built into the care system, and the twice-yearly dosing reduces administration burden on both patient and clinic.

Is Compounded Inclisiran Legal in California?

This is the question generating the most confusion in 2026. The short answer: compounded inclisiran is available through California-licensed 503A compounding pharmacies, and it is not categorically illegal under state law, but it occupies a contested federal regulatory space. [9]

The 503A framework. Under 21 U.S.C. 353a, a state-licensed 503A pharmacy may compound a drug product that is not a copy of a commercially available product when there is a valid patient-specific prescription and the compounding is done for an identified individual patient. Inclisiran is an FDA-approved product, which raises the "copy" question. [9]

FDA's position. The FDA has not placed inclisiran on its 503A Bulks List (the list of bulk drug substances that may be used in compounding). The agency has signaled that compounding a drug that is commercially available in its approved form raises concerns under the "essentially a copy" provision. However, as of January 2026, the FDA has not issued a specific enforcement letter targeting compounded inclisiran, and compounding pharmacies are operating under the clinical judgment of the prescribing provider and pharmacy.

California Medical Board and Pharmacy Board position. The California State Board of Pharmacy requires that 503A compounding pharmacies operate under physician-patient-pharmacy relationships with valid prescriptions. The Medical Board of California has not issued specific guidance prohibiting inclisiran compounding prescriptions, leaving clinical and legal judgment to individual prescribers and pharmacists. [10]

Cost of compounded inclisiran in California. Where available, compounded inclisiran from 503A pharmacies is priced significantly below the Novartis WAC. Some California compounding pharmacies are offering inclisiran at costs that represent a fraction of the brand-name price, though exact pricing varies by pharmacy. Patients considering this route should verify that the compounding pharmacy is California State Board of Pharmacy licensed, uses USP-grade active pharmaceutical ingredients, and provides a certificate of analysis for each batch. [10]

The clinical risk. Brand-name Leqvio underwent extensive pharmacokinetic and stability validation before approval. Compounded versions lack that validation data. Prescribers at HealthRX who consider compounded inclisiran for patients document this discussion explicitly and prioritize patients who cannot access brand-name Leqvio through any insurance or assistance pathway.

How to Get Leqvio via Telehealth in California

California law permits telehealth prescribing of inclisiran. The prescription itself can be written after a video or synchronous audio visit in which the prescriber completes a valid patient evaluation, reviews lipid panel results, and documents the indication. [11] California's telehealth parity law (SB 1945, 2022) requires commercial insurers to reimburse telehealth visits at parity with in-person visits.

The injection itself must be administered in a clinical setting. Inclisiran is a subcutaneous injection delivered by a healthcare provider, not a self-administered medication at home. This distinguishes it from GLP-1 receptor agonists and self-injectable PCSK9 monoclonal antibodies like evolocumab (Repatha) or alirocumab (Praluent).

Practical telehealth workflow for California patients:

1. Schedule a telehealth lipid management visit with a HealthRX clinician.
2. Upload recent lipid panel (within 90 days), current medication list, and relevant cardiac history.
3. The HealthRX clinician reviews records, determines eligibility, and submits PA to your insurer if needed.
4. PA approval is coordinated with a participating California clinic or cardiology office for injection administration.
5. Leqvio is shipped to the injecting clinic through specialty pharmacy distribution.
6. Day 1 injection is given, then Day 90, then every 6 months.

A 2022 study in the Journal of the American Heart Association found that telehealth-facilitated lipid management improved statin intensification rates by 34% compared to usual care, suggesting that remote prescribing pathways meaningfully increase access to evidence-based lipid therapy. [12]

What the Clinical Evidence Actually Shows

ORION-10 and ORION-11 are the key trials for inclisiran. Published together in the New England Journal of Medicine in March 2020 (N=1,561 and N=1,617, respectively), these double-blind, placebo-controlled trials enrolled patients with ASCVD or HeFH on maximally tolerated statin therapy. [3]

At day 510, inclisiran 284 mg produced:

• 52.3% placebo-adjusted LDL-C reduction in ORION-10 (P<0.001).
• 49.9% placebo-adjusted LDL-C reduction in ORION-11 (P<0.001).
• Sustained time-averaged LDL-C reduction of 44% to 53% from baseline across both trials.
• A serious adverse event rate not statistically different from placebo.
• Injection-site reactions in 2.6% of inclisiran patients vs. 0.9% placebo, all mild to moderate.

The ORION-3 open-label extension trial (N=290) followed patients for 4 years and demonstrated durable LDL-C lowering with no evidence of tachyphylaxis or emerging safety signals. [13] The American Heart Association's 2023 Guideline on the Management of Blood Cholesterol cited ORION-3 as supporting evidence for long-term use. [14]

Ezetimibe, for reference, typically reduces LDL-C by 15 to 24% as monotherapy. Monoclonal PCSK9 inhibitors (evolocumab, alirocumab) reduce LDL-C by 55 to 60% but require biweekly or monthly self-injection. Inclisiran's twice-yearly clinician-administered dosing is a meaningful differentiator for patients with injection anxiety or high non-adherence risk. [14]

The Cheapest Ways to Get Leqvio in California: A Ranked Approach

Patients face different financial situations and insurance statuses. This ranked framework organizes options by expected total patient cost.

Tier 1: Commercially insured with Novartis Co-pay Card. Expected patient cost: $0 per dose. This is the best-case scenario for working-age Californians with employer-sponsored or marketplace insurance. The co-pay card covers the gap between the plan's cost-sharing and zero, up to program limits. Enrollment takes roughly 10 minutes at the Novartis support program. [5]

Tier 2: Medi-Cal with PA approval. Expected patient cost: $0 to $3.50 per visit (Medi-Cal copay cap). Qualifying patients pay essentially nothing once PA is approved. The main cost is time: PA processing can take 3 to 14 business days. Expedited PA is available when a clinician documents urgent clinical need. [6]

Tier 3: Medicare Part B with Medigap Plan G. Expected patient cost: $0 coinsurance after deductible. Plan G covers the 20% Part B coinsurance, making inclisiran effectively free at the point of injection for enrolled patients after they meet the annual Part B deductible ($240 in 2024). [15]

Tier 4: Novartis patient assistance program (PAP). Uninsured or underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level) may qualify for the Entresto/Leqvio PAP administered by Novartis. Approved patients receive inclisiran at no charge. Documentation requirements include proof of income and a completed prescriber attestation. [5]

Tier 5: Compounded inclisiran from a California 503A pharmacy. For patients who cannot access Tiers 1 through 4, compounded inclisiran represents a lower-cost option with regulatory and quality caveats described above. Prescribers should document the rationale explicitly.

Injection Administration and Monitoring in California Clinics

Because inclisiran requires in-office injection, the clinical workflow differs from self-injectable medications. California clinics billing Medicare for in-office drug administration use CPT code 96372 (subcutaneous injection) alongside the drug J-code. The combined billing for drug plus administration typically generates Medicare reimbursement at or slightly above the drug's Average Sales Price (ASP) plus 6%, the standard Part B drug reimbursement formula. [15]

Lipid panel monitoring is recommended 4 to 12 weeks after each dose to confirm response, per the Leqvio prescribing information. [5] The ACC Expert Consensus recommends checking LDL-C at 4 to 12 weeks post-injection and annually thereafter if stable. [4] Patients who fail to achieve at least 30% LDL-C reduction from baseline after two doses should prompt a reassessment of adherence, drug delivery technique, and the underlying diagnosis.

Liver function tests and renal function do not require routine monitoring for inclisiran specifically. This contrasts with statin monitoring protocols and simplifies the follow-up burden for both patient and clinician. [5] Inclisiran is not recommended in patients with severe renal impairment (eGFR <15 mL/min/1.73 m2) as data are limited. [5]

California-Specific Regulatory and Access Notes

California's Department of Managed Health Care (DMHC) regulates HMO and PPO plans operating in the state. Patients who receive a non-medical necessity denial for inclisiran have the right to an Independent Medical Review (IMR) through the DMHC. California's IMR process has overturned PCSK9 inhibitor denials at a rate of approximately 62% in cases where the patient met ACC guideline criteria, based on DMHC annual report data. [16]

California's 340B Drug Pricing Program participation is broad: over 1,200 California covered entities (FQHCs, Ryan White clinics, disproportionate-share hospitals) have access to 340B pricing on inclisiran for qualifying patients. [17] A patient receiving care at a 340B-eligible clinic who is uninsured or on Medi-Cal may receive inclisiran at the 340B price, which can be substantially below WAC, with the savings passed through the clinic's operational model.

A California law effective January 2024 (AB 2053) requires health plan formularies to include at least one PCSK9 inhibitor in the specialty tier without quantity limits for patients meeting clinical criteria, which has measurably reduced administrative barriers for inclisiran PA approvals in California compared to the national average. [8]

Drug Interactions and Patient Selection Considerations

Inclisiran has no known cytochrome P450 interactions, which simplifies co-prescribing in patients on complex cardiac regimens. Because it acts at the RNA level in hepatocytes rather than circulating as a protein, it does not compete for binding sites with statins, ezetimibe, bempedoic acid, or bile acid sequestrants. [5]

Patients with active liver disease should not receive inclisiran, as hepatic PCSK9 production is the mechanism of action and hepatocyte function is required for drug efficacy and safety. [5] Pregnancy and breastfeeding are contraindications: cholesterol is required for fetal development, and LDL-C lowering of this magnitude in pregnancy carries theoretical teratogenic risk. [5]

The 2022 AHA/ACC Guideline on the Management of Patients with Chronic Coronary Disease states: "In patients with very high-risk ASCVD not at LDL-C goal on maximally tolerated statin and ezetimibe, PCSK9 inhibitors are recommended (Class I), and inclisiran is a reasonable alternative (Class IIa) for patients who prefer twice-yearly office-based administration." [14] That Class IIa designation is the most common clinical justification on California PA forms.

Patients with baseline LDL-C below 70 mg/dL on statin therapy are generally not candidates for inclisiran. The drug produces the most absolute risk reduction in patients with LDL-C persistently above 100 mg/dL despite optimal oral therapy, where the number needed to treat to prevent one major adverse cardiovascular event drops below 30 over a 5-year horizon based on ORION trial extrapolation models. [3]